Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 3
1954 1
1955 2
1956 2
1958 1
1961 2
1962 7
1963 13
1964 13
1965 18
1966 16
1967 16
1968 19
1969 25
1970 15
1971 24
1972 15
1973 15
1974 26
1975 29
1976 35
1977 36
1978 68
1979 70
1980 65
1981 69
1982 71
1983 76
1984 77
1985 90
1986 82
1987 106
1988 83
1989 110
1990 99
1991 115
1992 103
1993 99
1994 98
1995 135
1996 139
1997 125
1998 165
1999 167
2000 204
2001 214
2002 223
2003 222
2004 225
2005 238
2006 237
2007 255
2008 259
2009 230
2010 246
2011 275
2012 241
2013 232
2014 228
2015 204
2016 207
2017 219
2018 211
2019 247
2020 288
2021 269
2022 14
Text availability
Article attribute
Article type
Publication date

Search Results

7,229 results
Results by year
Filters applied: . Clear all
Page 1
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.
Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, Mutoh Y, Homma Y, Terada M, Ogawa T, Kashizaki F, Yokoyama T, Koba H, Kasahara H, Yokota K, Kato H, Yoshida J, Kita T, Kato Y, Kamio T, Kodama N, Uchida Y, Ikeda N, Shinoda M, Nakagawa A, Nakatsumi H, Horiguchi T, Iwata M, Matsuyama A, Banno S, Koseki T, Teramachi M, Miyata M, Tajima S, Maeki T, Nakayama E, Taniguchi S, Lim CK, Saijo M, Imai T, Yoshida H, Kabata D, Shintani A, Yuzawa Y, Kondo M. Doi Y, et al. Among authors: yoshida h. Antimicrob Agents Chemother. 2020 Nov 17;64(12):e01897-20. doi: 10.1128/AAC.01897-20. Print 2020 Nov 17. Antimicrob Agents Chemother. 2020. PMID: 32958718 Free PMC article. Clinical Trial.
Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy.
Hatae R, Chamoto K, Kim YH, Sonomura K, Taneishi K, Kawaguchi S, Yoshida H, Ozasa H, Sakamori Y, Akrami M, Fagarasan S, Masuda I, Okuno Y, Matsuda F, Hirai T, Honjo T. Hatae R, et al. Among authors: yoshida h. JCI Insight. 2020 Jan 30;5(2):e133501. doi: 10.1172/jci.insight.133501. JCI Insight. 2020. PMID: 31855576 Free PMC article.
Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study.
Yoshida Y, Yamada T, Kamiyama H, Kosugi C, Ishibashi K, Yoshida H, Ishida H, Yamaguchi S, Kuramochi H, Fukazawa A, Sonoda H, Yoshimatsu K, Matsuda A, Hasegawa S, Sakamoto K, Otsuka T, Koda K; TAS CC3 Study Group.. Yoshida Y, et al. Among authors: yoshida h. Int J Clin Oncol. 2021 Jan;26(1):111-117. doi: 10.1007/s10147-020-01794-8. Epub 2020 Oct 21. Int J Clin Oncol. 2021. PMID: 33083913 Clinical Trial.
In reply.
Yoshida H, Migita RT, Mazor SS. Yoshida H, et al. Ann Emerg Med. 2019 Sep;74(3):467-468. doi: 10.1016/j.annemergmed.2019.06.010. Ann Emerg Med. 2019. PMID: 31445553 No abstract available.
Diabetic dyslipidemia: evaluation and mechanism.
Yanai H, Hirowatari Y, Yoshida H. Yanai H, et al. Among authors: yoshida h. Glob Health Med. 2019 Oct 31;1(1):30-35. doi: 10.35772/ghm.2019.01007. Glob Health Med. 2019. PMID: 33330752 Free PMC article. Review.
Hypothermia-Induced Hypokalemia.
Yoshida H, Reeve W, Mansoor AM. Yoshida H, et al. Am J Med. 2021 May;134(5):e319-e320. doi: 10.1016/j.amjmed.2020.09.054. Epub 2020 Nov 8. Am J Med. 2021. PMID: 33176124 No abstract available.
7,229 results